| 09.01. | Nektar Therapeutics : Results of Operations and Financial Condition, Regulation FD Disclos.. |  |
| 05.01. | Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P.. | |
| 04.01. | Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P.. | |
| 2022 | Nektar Therapeutics : Other Events (form 8-K) | |
| 2022 | Nektar Therapeutics : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Fin.. | |
| 2022 | Nektar Therapeutics to Host Investor & Analyst Event on December 12th | |
| 2022 | Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Pro.. | |
| 2022 | Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Dem.. | |
| 2022 | NEKTAR THERAPEUTICS Management's Discussion and Analysis of Financial Condition and Re.. | |
| 2022 | Nektar : Q3 Earnings Snapshot | |
| 2022 | Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q3 Revenue $23.6M | |
| 2022 | Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q3 Revenue $23.6M, vs. Street Est of .. | |
| 2022 | Nektar Therapeutics Reports Earnings Results for the Third Quarter and Nine Months Ende.. | |
| 2022 | Nektar to Announce Financial Results for the Third Quarter 2022 on Thursday, November 3.. | |
| 2022 | Nektar Therapeutics : NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, I.. | |
| 2022 | Nektar Therapeutics : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-.. | |
| 2022 | Pound Could Fall Further as BOE's Gilt Intervention Ends Soon | |
| 2022 | BOE's Decision to Buy Index-Linked Gilts Could Reduce Aggressive Selling | |
| 2022 | FTSE 100 Falls as Jobs Data Fuel BOE Rate Rise Bets | |
| 2022 | Longer Period of Support for Gilts Could Be Necessary, Says ING | |
| 2022 | EN DIRECTO DESDE LOS MERCADOS: Telefónica, BBVA, Airbus, .. |  |
| 2022 | FTSE 100 Seen Lower Again as Risk Aversion Continues | |
| 2022 | Qui capitulera en premier ? |  |
| 2022 | EN DIRECT DES MARCHES : Airbus, BNP Paribas, Sanofi, EDF, TSMC, Gi.. | |
| 2022 | PureTech Health Terminates Merger Discussions With Nektar Therapeutics | |
| 2022 | Nektar Therapeutics cancelled the acquisition of PureTech Health plc. | |
| 2022 | Form 8 (OPD) Nektar Therapeutics, Inc. | |
| 2022 | FTSE Closed Lower Despite Positive US Jobs Data | |
| 2022 | PureTech Health, Nektar Therapeutics Shares Decline After Confirming Merger Talks | |
| 2022 | Wall Street Set to Open Lower as Jobs Report Shows Tight Labor Market | |
| 2022 | US Futures Mixed Ahead of September Jobs Report | |
| 2022 | Top Premarket Decliners | |
| 2022 | Nektar Therapeutics : Statement regarding recent press speculation - Form 8-K | |
| 2022 | Nektar Therapeutics : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-.. | |
| 2022 | FTSE 100 Struggles in Cautious Trade Before U.S. Jobs Data | |
| 2022 | Sterling Unlikely to Stay Above $1.10 For Long, ING Says | |
| 2022 | Outlook for Gilts Remains Bearish, Says Citi | |
| 2022 | London Stocks Seen Lower; Investors on Edge Ahead of US Jobs Data | |
| 2022 | PureTech Health Confirms Merger Negotiations with Nektar Therapeutics | |
| 2022 | Nektar Therapeutics submitted a non-binding proposal to acquire PureTech Health plc. | |
| 2022 | Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with At.. | |
| 2022 | Nektar Therapeutics Presents Data for Rezpegaldesleukin in Patients with Atopic Dermati.. | |
| 2022 | Insider Sell: Nektar Therapeutics | |
| 2022 | Nektar Therapeutics Announces Preclinical Publication of Data for NKTR-255 and Its Obse.. | |
| 2022 | North American Morning Briefing: Stocks to -2- | |
| 2022 | NEKTAR THERAPEUTICS Management's Discussion and Analysis of Financial Condition and Re.. | |
| 2022 | Nektar : Q2 Earnings Snapshot | |
| 2022 | Nektar Therapeutics : Reports Second Quarter 2022 Financial Results - Form 8-K | |
| 2022 | Nektar Therapeutics Provides Earnings Guidance for the Year 2022 | |
| 2022 | Earnings Flash (NKTR) NEKTAR THERAPEUTICS Posts Q2 Revenue $21.6M | |
| 2022 | Nektar Therapeutics Reports Second Quarter 2022 Financial Results | |
| 2022 | Nektar Therapeutics Reports Earnings Results for the Second Quarter and Six Months Ende.. | |
| 2022 | Nektar to Announce Financial Results for the Second Quarter 2022 on Thursday, August 4,.. | |
| 2022 | BB Biotech: in 2* trim perdita di 233 mln chf (+129 mln in 2021) |  |
| 2022 | Nektar Therapeutics : Change in Directors or Principal Officers (form 8-K) | |
| 2022 | Nektar Therapeutics Promotes Jillian Thomsen to CFO | |
| 2022 | Nektar Announces Promotion of Jillian B. Thomsen to Senior Vice President & Chief Finan.. | |
| 2022 | Nektar Promotes Jillian B. Thomsen to Chief Financial Officer | |
| 2022 | Nektar Promotes Jillian B. Thomsen to Senior Vice President | |
| 2022 | Nektar Therapeutics(NasdaqGS:NKTR) added to Russell 2000 Va.. | |
| 2022 | Nektar Therapeutics(NasdaqGS:NKTR) dropped from Russell 100.. | |
| 2022 | Nektar Therapeutics(NasdaqGS:NKTR) added to Russell 2000 In.. | |
| 2022 | Nektar Therapeutics(NasdaqGS:NKTR) dropped from Russell 100.. | |
| 2022 | Nektar Therapeutics(NasdaqGS:NKTR) dropped from Russell Mid.. | |
| 2022 | Nektar Therapeutics(NasdaqGS:NKTR) dropped from Russell 100.. | |
| 2022 | Nektar Therapeutics(NasdaqGS:NKTR) dropped from Russell Mid.. | |
| 2022 | Nektar Therapeutics(NasdaqGS:NKTR) added to Russell 2000 Dy.. | |
| 2022 | Nektar Therapeutics : Submission of Matters to a Vote of Security Holders (form 8-K) | |
| 2022 | Nektar Therapeutics : 2022 Annual Shareholder Meeting Presentation | |
| 2022 | Nektar Therapeutics : Other Events (form 8-K) | |
| 2022 | Nektar Therapeutics Reviews Interim Efficacy and Safety Data from the Ongoing Phase 2 D.. | |
| 2022 | This Week At The Ninth : Cancer Drugs And COVID Grants | |
| 2022 | NEKTAR THERAPEUTICS Management's Discussion and Analysis of Financial Condition and Re.. | |
| 2022 | Nektar : Q1 Earnings Snapshot | |
| 2022 | Earnings Flash (NKTR) NEKTAR THERAPEUTICS Posts Q1 Revenue $24.8M | |
| 2022 | Nektar Therapeutics Reports Earnings Results for the First Quarter Ended March 31, 2022 | |
| 2022 | Nektar Therapeutics Reports First Quarter 2022 Financial Results | |
| 2022 | Nektar Therapeutics : Costs Associated with Exit or Disposal Activities, Material Impairme.. | |
| 2022 | Nektar to cut over 500 jobs following cancer drug failure | |
| 2022 | Nektar Therapeutics Plans to Focus Resources on Key Research; Cuts 70% of Workforce; Ex.. | |
| 2022 | Nektar Therapeutics : Announces Strategic Reorganization Plan and Corporate Outlook - Form.. | |
| 2022 | Nektar Therapeutics : Results of Operations and Financial Condition, Change in Directors o.. | |
| 2022 | John Northcott Step Down as Senior Vice President and Chief Commercial Officer of Nekta.. | |
| 2022 | Nektar and Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15 Receptor A.. | |
| 2022 | Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors to Outline.. | |
| 2022 | Correction: Sector Update: Health Care Stocks Stumble Monday Afternoon | |
| 2022 | Sector Update: Health Care Stocks Stumble Monday Afternoon | |
| 2022 | Sector Update: Health Care Stocks Retreating to Begin New Week | |
| 2022 | Nektar Therapeutics Plunges After Joint Trials With Bristol-Myers Squibb Stopped for Ca.. | |
| 2022 | Top Midday Decliners | |
| 2022 | Sector Update: Health Care Stocks Modestly Lower Pre-Bell Monday | |
| 2022 | Wall Street Set for Narrow Losses Amid Rising Bond Yields | |
| 2022 | Top Premarket Decliners | |
| 2022 | Nektar Therapeutics, Bristol-Myers Squibb Stop Trials of Cancer Combination Therapy | |
| 2022 | Nektar stops clinical trials for key cancer drug, shares tumble | |
| 2022 | Nektar, Bristol Myers to Discontinue Bempeg Clinical Development Program | |
| 2022 | Nektar Therapeutics : and Bristol Myers Squibb Announce Update on Clinical Development Pro.. | |
| 2022 | Nektar Therapeutics : Other Events, Financial Statements and Exhibits (form 8-K) | |
| 2022 | Nektar, Bristol Myers end clinical trial program for cancer drug combo | |
| 2022 | Nektar Therapeutics and Bristol-Myers Squibb Company Announce Update on Clinical Develo.. | |
Google
Twitter
Facebook
Apple
English (USA)
English (UK)
English (Canada)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Bericht
